The Joint Venture with Novartis is a mess - Avis employé Employé (anonyme) GSK

3,0
9 juin 2015
Employé (anonyme)
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Compensation, Big Brands, OTC Switch capability

Inconvénients

The Joint Venture with Novartis is all about cutting costs. The new GSK will be way too lean. I fear the GSK I know and love will be long gone in a few months. The transition will be long and difficult. Many things will fall trought the cracks and GSK will be less customer focused and even more focused on saving a buck. The poor performance of Big Pharma has made life difficult for Consumer Healthcare as we need to help the broader company keep the dividends high.

Découvrez plus d’avis sur GSK

5,0
6 mai 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Development Pay People Expertise Coaching

Inconvénients

Site management turnover lead to stability issues

2,0
10 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

The benefits were great, pay was middle of the road all things considered.

Inconvénients

Mangement left things to be desired.

Voir les avis par: Utile|Évaluation|Date|Tout